Clinical trials: Visual Suppression
Inflammation
Efficacy of Ketorolac 0.4% in Prostaglandin Suppression
A pilot study to evaluate the extent of PGE2 inhibition (mean aqueous values) by Ketorolac 0.04% following peripheral iridotomy
- Trial name
- NCT00791323
- Testing
- Ketorolac 0.4%, Lubricating Eye Drop
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Allergan
Kidney Transplantation
A Study in Kidney Transplant Subjects to Investigate the Optimal Suppression of Immunity to Help Prevent Kidney Rejection
To compare how well the new formulation of Tacrolimus® used once daily, in combination with other drugs helps prevent the rejection of a new kidney after transplantation compared to the twice daily dose of Tacrolimus
- Trial name
- OSAKA (NCT00717470)
- Testing
- Prograf®, Advagraf®, Mycophenolate Mofetil
- Where
- 110 sites in Argentina, Austria and 20 more
- Volunteers
- 1,252 people
- Sponsor
- Astellas Pharma Inc
Bone Marrow Suppression
Clinical Study on the Safety and Efficacy of Umbilical Cord Blood Infusion in Treating Bone Marrow Suppression .
The clinical study aims to evaluate the safety and efficacy of umbilical cord blood transfusion in treating bone marrow suppression after chemotherapy in elderly patients with MDS and AML
- Trial name
- NCT07201233
- Testing
- Umbilical cord blood
- Volunteers
- 30 people
- Sponsor
- Shandong Qilu Stem Cells Engineering Co., Ltd.
Dermatitis, Atopic
Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Atopic Dermatitis
this study is to evaluate the potential of DSXS to suppress HPA axis function in patients with moderate to severe atopic dermatitis.
- Trial name
- NCT02595008
- Testing
- DSXS
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
HIV Infections
A Phase IIIB Study Evaluating the Effect on Serum Lipids Following a Switch to Atazanavir in HIV Infected Subjects Evidencing Virologic Suppression on Their First PI-Based Antiretroviral Therapy
The purpose of this clinical research study is to learn if atazanavir is associated with serum LDL cholesterol in HIV-infected subjects following a substitution of atazanavir for their previously administered protease inhibitor.
- Trial name
- NCT00067782
- Testing
- Atazanavir (immediate switch), Atazanavir (Week 24 switch)
- Where
- 19 sites in United States
- Sponsor
- Bristol-Myers Squibb
Normal Healthy Subject Population
Comparison of Prilosec OTC® Versus Zegerid® for Gastric Acid Suppression
The purpose of this study is to compare Prilosec OTC® and Zegerid® in their effects on gastric acid suppression.
- Trial name
- NCT00808769
- Testing
- Zegerid®, Prilosec OTC®
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Procter and Gamble
Psoriasis
DFD06 Cream vs Clobetasol Propionate Cream, 0.05% Hypothalamic- Pituitary-Adrenal (HPA) Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis
The purpose of this study is to evaluate the potential of DFD06 cream to suppress the HPA (hypothalamic-pituitary-adrenal) axis as compared to clobetasol propionate cream, 0.05% cream when applied twice daily for 15 days.
- Trial name
- HPA axis (NCT02131324)
- Testing
- DFD06 Cream, Clobetasol Propionate Cream 0.05%
- Where
- 15 sites in United States
- Volunteers
- 50 people
- Sponsor
- Promius Pharma, LLC
Plaque Psoriasis
DFD01 Spray HPA Axis Suppression Study in Adolescent Patients With Moderate to Severe Plaque Psoriasis
To evaluate the potential of DFD-01 (betamethasone dipropionate) Spray, 0.05% to suppress the hypothalamic-pituitary-adrenal (HPA) axis.
- Trial name
- NCT02527421
- Testing
- DFD01 Spray
- Where
- 8 sites in United States
- Volunteers
- 3 people
- Sponsor
- Primus Pharmaceuticals
COVID-19
Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Patients With COVID-19
This will be a phase 1a randomized, open label, multi-center study with approximately 24 subjects. All subjects will receive standard of care (SOC) per institutional guidelines for treatment of hospitalized patients with COVID-19…
- Trial name
- CRISIS (NCT04425252)
- Testing
- Brequinar, Standard of Care
- Where
- 5 sites in United States
- Volunteers
- 25 people
- Sponsor
- Clear Creek Bio, Inc.
Plaque Psoriasis
Multiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Treatment With Halobetasol Spray in Patients With Plaque Psoriasis
This is an open-label, safety study designed to assess the multiple-dose pharmacokinetics and potential for adrenal suppression following topical treatment with halobetasol propionate 0.05% spray applied twice-daily in adult…
- Trial name
- NCT03298581
- Testing
- Halobetasol Propionate
- Sponsor
- Sun Pharmaceutical Industries Limited
Atopic Dermatitis
Clobetasol Topical Oil for Children With Moderate to Severe Atopic Dermatitis
Open-Label Study designed to evaluate the HPA axis suppression potential of Clobetasol Topical Oil and pharmacokinetic safety / systemic exposure to clobetasol when Clobetasol Topical Oil is applied to pediatric subjects with…
- Trial name
- NCT03847389
- Testing
- Clobetasol propionate 0.05% Topical Oil
- Where
- 6 sites in United States
- Volunteers
- 8 people
- Sponsor
- Hill Dermaceuticals, Inc.
Metabolic Syndrome
The BANGALORE Study; Combination of Berberine, Lipoic Acid, and Picrorhiza
Though medical treatment has been effective in the treatment of cardiometabolic diseases (including coronary atherosclerosis and diabetes mellitus), the incidence of these disorders continues to be high.
- Trial name
- CAR-191 (NCT01696448)
- Testing
- CAR-191
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Carmel Biosciences
Photosensitive Epilepsy, Epilepsy
A Double Blind, Randomized, Cross-over Study Examining the Suppression of the Photoparoxysmal EEG Response With NPT 2042
A double-blind, placebo-controlled, crossover trial to investigate the PPR of approximately 5 subjects with a known stable PPR on EEG, using 2 doses of NPT 2042 compared to placebo.
- Trial name
- NCT06525649
- Testing
- NPT 2042
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- NeuroPro Therapeutics, Inc.